reference/24704931

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24704931

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article
endingPage	9
issn	1021-335X 1791-2431
issueIdentifier	4
pageRange	885-9
publicationName	Oncology Reports
startingPage	885
bibliographicCitation	Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E, Solomon J, Sundaram M, Feun L, Savaraj N. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncol Rep. 2003 Jul;10(4):885–9. doi: 10.3892/or.10.4.885. PMID: 12792740.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9c5942332ab49f87255a6b65cb77e33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_73b4fc1162c8d62fc56360f4cf97437b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_408beb90f7674d7561ca782a76661b9f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ab2fdfb3909a7e35dbc020a4584d9f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d884f189772c455419cff36b548749d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c687bda559b7237b9864043872c2f75 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d081190496752db319976d0eb86bf7d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32310a8e91d890dcecff3de381a414f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5fe8175cf8e5965ab2bd8bcd66ef4cad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a39f5061a26743c1b2de7a2d4c2aa1e
date	2003-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3892/or.10.4.885 https://pubmed.ncbi.nlm.nih.gov/12792740
isPartOf	https://portal.issn.org/resource/ISSN/1021-335X https://portal.issn.org/resource/ISSN/1791-2431 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/20608
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer
discusses	http://id.nlm.nih.gov/mesh/M0022672 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0026444 http://id.nlm.nih.gov/mesh/M0097344
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011471Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D009376Q000188 http://id.nlm.nih.gov/mesh/D014747Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D011471Q000473 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D014747Q000008 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D017430Q000378 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D000077235 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D000230Q000188 http://id.nlm.nih.gov/mesh/D000230Q000556 http://id.nlm.nih.gov/mesh/D001859Q000188 http://id.nlm.nih.gov/mesh/D001859Q000556 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71296871 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60780 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46931011 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44424639 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73265388 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13200033 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311497 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5672 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136123131

Total number of triples: 72.